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DEBATE-statistical analysis plans for
observational studies
Bart Hiemstra1* , Frederik Keus2, Jørn Wetterslev3, Christian Gluud3 and Iwan C. C. van der Horst4
Abstract
Background: All clinical research benefits from transparency and validity. Transparency and validity of studies may
increase by prospective registration of protocols and by publication of statistical analysis plans (SAPs) before data
have been accessed to discern data-driven analyses from pre-planned analyses.
Main message: Like clinical trials, recommendations for SAPs for observational studies increase the transparency
and validity of findings. We appraised the applicability of recently developed guidelines for the content of SAPs for
clinical trials to SAPs for observational studies. Of the 32 items recommended for a SAP for a clinical trial, 30 items
(94%) were identically applicable to a SAP for our observational study. Power estimations and adjustments for
multiplicity are equally important in observational studies and clinical trials as both types of studies usually address
multiple hypotheses. Only two clinical trial items (6%) regarding issues of randomisation and definition of
adherence to the intervention did not seem applicable to observational studies. We suggest to include one new
item specifically applicable to observational studies to be addressed in a SAP, describing how adjustment for
possible confounders will be handled in the analyses.
Conclusion: With only few amendments, the guidelines for SAP of a clinical trial can be applied to a SAP for an
observational study. We suggest SAPs should be equally required for observational studies and clinical trials to
increase their transparency and validity.
Background
Transparency is considered fundamental for the reproduci-
bility of any research finding [1]. Initiatives such as SPIRIT,
CONSORT, PRISMA, and PROSPERO have contributed to
transparent reporting of protocols and findings of rando-
mised clinical trials and systematic reviews [2–5]. Still, the
multitude of decisions taken during the statistical analysis
phase of any study have been shown to impact on results
and conclusions, irrespective of pre-published protocols [6].
While any protocol for a clinical study should include the
principle features of the statistical analysis of the data, a stat-
istical analysis plan (SAP) should fully outline the details of
all planned analyses, including any additional analyses. Re-
cently, Gamble and colleagues used a Delphi survey to reach
consensus and provide recommendations for a minimum
set of items that should be addressed in a SAP for a rando-
mised clinical trial [7].
Observational studies are frequently the source for
multiple statistical analyses and reports. Guidelines for
reporting such as STROBE, TRIPOD or STARD are key
to transparent reporting of findings of observational
studies [8–10], but these do not reduce the number of
possible decisions taken during the analysis phase of
such studies. Like randomised clinical trials, the validity
of conclusions of cohort studies is likely to improve by
use of published SAPs to distinguish pre-planned ana-
lyses from data-driven exercises [1, 11]. Journals now en-
courage researchers to preregister observational studies
and SAPs [11–15], but there are no guidelines on the re-
quired content of the latter.
Therefore, we argue that SAP guidelines should also
be developed for observational studies. In the absence of
such a guideline, we appraised and modified recently de-
veloped recommendations for the content of SAPs for
clinical trials to be used for observational studies. This
paper reports the applicability of SAP guidelines for
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clinical trials to our single-centre observational study, of
which the study design is described elsewhere [16].
Main text: recommended content of SAPs in
observational studies
We have appraised the recommendations for the content
of SAPs for clinical trials and assessed the applicability
of each section to be used for an observational study
(Table 1). We added the item ‘confounding’ to the rec-
ommended list for observational studies. Compared to
clinical trials, confounding is an even more pronounced
issue in observational studies and should be considered
during model building.
The SAP of our observational study, the Simple Inten-
sive Care Studies (SICS)-I, is presented as an example
document (Additional file 1). This SAP was written as
an add-on document to a pre-published protocol on
clinicaltrials.gov [NCT02912624]. In absence of guide-
lines for observational study protocols, we used the first
20 items from the SPIRIT as a backbone for our obser-
vational study protocol (Additional file 2).
Section 1: administrative information
The administrative information section in a SAP for an
observational study is equally applicable to the content
of a SAP for a randomised clinical trial. Item 1a and 1b
were renamed while the content remained the same.
For item 1b; a protocol of an observational study can
be registered in a dedicated database (e.g. clinicaltrials.-
gov, researchregistry.com) alike randomised clinical tri-
als [14, 17]. The description of item 4 was rephrased
since in observational studies usually no interim ana-
lyses are planned (Table 1). All other items, names, and
descriptions were left unchanged.
Section 2: introduction
The introduction section in a SAP for an observational
study is equal to the content of a SAP for a randomised
clinical trial.
Section 3: study methods
Sample size
Unlike randomised clinical trials that calculate a sample
size to study an intervention effect taking power into
consideration, the sample sizes of most observational
studies are influenced by other factors (e.g. resources,
time restrictions, convenience). Accordingly, most obser-
vational studies will have a given sample size and, if suf-
ficiently large, affording enough power. The STROBE
guidelines only expect authors to explain how the study
size was arrived at [8], which may reduce the incentive
to conduct sample size calculations for observational
studies.
When there is a given sample size or if a sample size
was not specified in the protocol, we suggest providing
power considerations for the primary analysis of the ob-
servational study to limit random errors. The power
considerations necessitate a definition of a minimally
important difference or intervention effect in the
presence of a given sample size. Any power calcula-
tion provides the chance of a type-II error (false
negative findings), while a detectable difference may
be clinically more informative. For example, it shows
the minimal relative risk that can be detected with
the specified power and sample size given a type I
error probability α.
Framework
While causality can never be proven in observational
studies, observed associations may fuel hypotheses that
later can be tested in randomised clinical trials [18]. Al-
though the vast majority of observational studies test for
superiority, there are some that address equivalence and
non-inferiority hypotheses [19–22]. Of course, con-
founding will always be present in any of these frame-
works. Nevertheless, a SAP should describe whether the
relevant hypothesis was assessed for superiority, equiva-
lence or non-inferiority.
Statistical interim analyses and stopping guidance
Interim analyses are typically known to guide rando-
mised clinical trials for early stopping due to benefit,
harm or futility of tested interventions. Investigators
are ethically obliged to conduct interim analyses to re-
duce study patients’ exposure to an inferior interven-
tion. While there is usually no intervention component
in observational studies which can be halted, there
may be incentives to perform interim analyses for early
stopping of continued (costly) data collections due to
already clear observed associations or futility. Further-
more, observational studies may be subject to repeated
testing of accumulating data, which needs adjustment
of significance levels to reduce inflated type-I errors
(false positive findings), such as those described by
O’Brien & Fleming [23]. Such methods should be de-
scribed in the SAP.
Timing of final analysis
A SAP for a blinded clinical trial should be published
prior to unblinding the data or prior to the randomisa-
tion of the first participant in case of an open clinical
trial. Likewise, a SAP for prospective observational stud-
ies should also be published before the first participant
is included or at least all access to the database should
be restricted. Randomised clinical trials that include
blinding have a natural advantage that interventions can
be coded during the statistical analyses. Such coding of
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Table 1 Applicability of recommend content of statistical analysis plans for clinical trials to observational studies
Section/Item Index Description for clinical trials Description for observational studies
Section 1: Administrative information
Title and study
registration
1a Descriptive title that matches the protocol, with SAP
either as a forerunner or subtitle, and trial acronym
Descriptive title that matches the protocol, with SAP
either as a forerunner or subtitle, and study acronym
1b Trial registration number Study registration number
SAP version 2 SAP version number with dates Unchanged
Protocol version 3 Reference to version of protocol being used Unchanged
SAP revisions 4a SAP revision history Unchanged
4b Justification for each SAP revision Unchanged
4c Timing of SAP revisions in relation to interim analyses,
etc.




5 Names, affiliations, and roles of SAP contributors Unchanged
Signatures of: 6a Person writing the SAP Unchanged
6b Senior statistician responsible Unchanged




7 Synopsis of trial background and rationale including a brief
description of research question and brief justification for
undertaking the trial
Synopsis of study background and rationale including a
brief description of research question and brief
justification for undertaking the study
Objectives 8 Description of specific objectives and hypotheses Description of specific objectives and hypotheses,
including secondary objectives
Section 3: Study methods
Study design 9 Brief description of trial design including type of trial (e.g.
parallel group, multi-arm, crossover, factorial and allocation
ratio and may include brief description of interventions)
Brief description of study design including type of study
(e.g. case-control, cross-sectional or cohort study)
Randomization 10 Randomization details, e.g., whether any minimization or
stratification occurred (including stratifying factors used or





11 Full sample size calculation or reference to sample size
calculation in protocol (instead of replication in SAP)
In case of an unspecified sample size, provide power
calculations for (at least) the primary analysis or present a
detectable difference with a specified power*
Framework 12 Superiority, equivalence, or noninferiority hypothesis
testing framework, including which comparisons will be





13a Information on interim analyses specifying what interim
analyses will be carried out and listing of time points
Information on repetitive analyses specifying what
repetitive analyses will be carried out and listing of time
points*
13b Any planned adjustment of the significance level due to
interim analysis
Any planned adjustment of the significance level due to
repetitive analyses
13c Details of guidelines for stopping the trial early Details of guidelines for stopping the study early
Timing of final
analysis
14 Timing of final analysis, e.g., all outcomes analysed






15 Time points at which the outcomes are measured
including visit “windows”
Unchanged




16 Level of statistical significance Unchanged*
17 Description and rationale for any adjustment for
multiplicity and, if so, detailing how the type 1 error is to
be controlled
Unchanged*
18 Confidence interval to be reported Unchanged
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Table 1 Applicability of recommend content of statistical analysis plans for clinical trials to observational studies (Continued)




19a Definition of adherence to the intervention and how this is
assessed including extent of exposure
Not applicable
19b Description of how adherence to the intervention will be
presented
Not applicable
19c Definition of protocol deviations for the trial Definition of protocol deviations for the study





20 Definition of analysis populations, e.g., intention to treat,
per protocol, complete case, safety
Definition of analysis populations, e.g., per protocol,
complete case, safety
Section 5: Study Population
Screening data 21 Reporting of screening data (if collected) to describe
representativeness of trial sample
Reporting of screening data (if collected) to describe
representativeness of study sample
Eligibility 22 Summary of eligibility criteria Unchanged
Recruitment 23 Information to be included in the CONSORT flow diagram Information to be included in the STROBE flow diagram
Withdrawal/
follow-up
24a Level of withdrawal, e.g., from intervention and/or from
follow-up
Level of withdrawal, e.g., dropouts after inclusion or refusal
to be contacted for additional information
24b Timing of withdrawal/lost to follow-up data Unchanged
24c Reasons and details of how withdrawal/lost to follow-up




25a List of baseline characteristics to be summarized Unchanged






– – A description of potential confounding covariates and how




List and describe each primary and secondary outcome
including details of:
26a Specification of outcomes and timings. If applicable
include the order of importance of primary or key
secondary end points (e.g., order in which they will be
tested)
Unchanged
26b Specific measurement and units (e.g., glucose control,
HbA1c [mmol/mol or %])
Unchanged
26c Any calculation or transformation used to derive the
outcome (e.g., change from baseline, QoL score, time to
event, logarithm, etc)
Unchanged
Analysis methods 27a What analysis method will be used and how the
treatment effects will be presented
Unchanged*
27b Any adjustment for covariates Unchanged
27c Methods used for assumptions to be checked for statistical
methods
Unchanged
27d Details of alternative methods to be used if distributional
assumptions do not hold, e.g., normality, proportional
hazards, etc
Unchanged
27e Any planned sensitivity analyses for each outcome where
applicable
Unchanged*
27f Any planned subgroup analyses for each outcome
including how subgroups are defined
Unchanged*
Missing data 28 Reporting and assumptions/statistical methods to handle




29 Details of any additional statistical analyses required, e.g.
complier-average causal effect analysis
Unchanged
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interventions is usually not in question in observational
studies, but it should be possible to mask the statistician
by using coding for several covariates (at least dichotom-
ous and categorical). Except for the study monitors, re-
searchers should be unable to read the database before
the study is finished or a SAP is written. If all study data
were accessible to the researchers, a detailed SAP may
still provide transparency on the intended analytic steps
and may prevent ‘fishing’ for statistically significant pre-
dictors in analyses or other manipulations of the data.
Any analysis that was not prespecified in the protocol
and/or the SAP can only be explorative in nature, which
should be described accordingly (i.e. exploratory or post-
hoc analysis).
Section 4: statistical principles
Multiplicity and type I errors
Multiplicity issues are similar in randomised clinical trials
and in observational studies, but rarely addressed in the
latter. Most observational studies ignore multiplicity issues
by testing in multiple analyses at the same conventional
P < 0.05 significance level. This increases the risks of a
family wise error rate (FWER), that is the type I error of at
least one false positive finding. Several methods have been
suggested to adjust for multiplicity, such as those accord-
ing to Bonferroni or Šidák [24, 25]. Even though Inter-
national Conference on Harmonization of Good Clinical
Practice guidelines recommend full Bonferroni adjustment
[26], such an adjustment may be too conservative in cor-
related outcomes of observational studies [27].
For example, the SICS-I addresses six different pri-
mary outcomes spread out across 13 hypotheses [16].
Our outcomes cardiac output, acute kidney injury, and
mortality are all affected by a patient’s haemodynamic
status, so that most outcomes will probably be positively
correlated. Since the Bonferroni adjustment assumes
that outcomes are unrelated, we used an adjustment of
our significance level that was pragmatic and probably
more accurate. For more details we refer to the paper by
Jakobsen and colleagues [28].
Section 5: study population
Recruitment
It is necessary to elucidate the numbers of eligible and
included patients of an observational study in a flow dia-
gram, preferably according to the STROBE recommen-
dations [29].
Potential confounding covariates
Results of observational studies can be seriously biased
by confounding covariates. The randomisation proced-
ure is used in randomised clinical trials to reduce the
imbalance in observed and unobserved confounders be-
tween the allocated groups, although success can never
be guaranteed [30]. The STROBE guidelines advocate to
address the rate of confounding; however, it was recently
shown that adherence to this statement is suboptimal
[31]. A SAP could serve to predefine confounders, and
how to address the expected rate of residual confound-
ing by adjustment, or stratification.
Confounding variables are key important to address
in observational studies. Usually, datasets of observa-
tional studies include large amounts of variables with
many inevitably correlated to each other. For example,
the SICS-I database contained 19 clinical examination
findings which all reflected (a part of) the haemo-
dynamic status of a patient. Next to expected con-
founding factors, the values of the variables can also
be confounded by unmeasured factors such as
environmental, genetic, or psychological influences.
Table 1 Applicability of recommend content of statistical analysis plans for clinical trials to observational studies (Continued)
Section/Item Index Description for clinical trials Description for observational studies
Harms 30 Sufficient detail on summarizing safety data, e.g.
information on severity, expectedness, and causality;
details of how adverse events are coded or categorized;
how adverse event data will be analysed, i.e. grade ¾ only,
incidence case analysis, intervention emergent analysis
Only applies when interventions are studied. Sufficient detail
on summarizing safety data, e.g. information on severity,
expectedness, and associations; details of how adverse
events are scored; how adverse event data will be
analysed and the follow-up time.*
Statistical software 31 Details of statistical packages to be used to carry out
analysis
Unchanged
References 32a References to be provided for nonstandard statistical
methods
Unchanged
32b Reference to Data Management Plan Unchanged
32c Reference to the Trial Master File and Statistical Master File Reference to the Study Master File and Statistical Master
File
32d Reference to other standard operation procedures to be
adhered to
Unchanged
This table was adapted with permission from Gamble et al. [7]. Italic text highlights a rephrased word/sentence in the modified description for observational
studies. An asterisk (*) indicates that a more elaborate description is present in our manuscript
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Therefore, we suggest to provide an a priori list of po-
tentially confounding variables (both ‘measured’ and
‘unmeasured’) so that the reader is better able to as-
sess the degree of residual confounding. Prelisting all
potential variables and the approach to model building
should be a main concern, if not the most important
issue, in the SAP of observational studies.
Section 6: analysis
Analysis methods
Analysis methods of clinical trials and observational
studies are different, yet both study types are suspicious
of selective reporting when no SAP is written [32]. Many
decisions are needed during the analysis phase of an ob-
servational study and all that can be foreseen should be
prespecified. An extensive description of the planned
statistical analyses, all covariates, and all considerations
need to be prespecified and detailed, which can only be
done in a SAP. The usually short statistical analysis sec-
tion of a manuscript does not allow a detailed explan-
ation, nor can it guarantee the prespecified status of the
analysis.
Sensitivity and subgroup analyses
The cost- and time-intensive nature of a randomised
clinical trial necessitates a strict protocol in which all
sensitivity and subgroup analyses are (usually) specified.
In observational studies, these additional analyses are
seldomly specified beforehand. A SAP is an opportunity
for authors to prove that they had prespecified inten-
tions of their sensitivity and subgroup analyses.
Missing data
Observational studies are particularly prone to miss-
ing data, but often do not address the mechanism of
missing values. Complete case analyses in the pres-
ence of missing data are associated with bias, when
data are not missing completely at random [33, 34].
Tests to identify the patterns and type of missing
data, and the statistical methods to handle missing
values should be described in a SAP. Examples in-
clude multiple imputations for data missing at ran-
dom or worst-best and best-worst case scenarios for
data missing not at random [34, 35].
Harms
Randomised clinical trials are costly and therefore often
limited in size and length of follow-up, so that rare
harms or late harms (e.g. after decades) remain un-
detected. Observational studies and post-marketing
phase IV randomised clinical trials are much more suit-
able for detection of rare or late harms [35], of which
the cardiovascular harms of clarithromycin in patients
with stable coronary heart disease or cyclooxygenase-2
(cox-2) inhibitors are good examples [36, 37]. This item
only applies to observational studies with a research
questions focusing on an intervention effect. Our SICS-I
cohort, for example, was not designed to study such
associations.
Applicability of SAP guidelines developed for randomised
clinical trials to observational studies
Of the 32 proposed items by Gamble and colleagues
(Table 1) [7], 30 items (94%) were also more or less dir-
ectly applicable to a SAP for an observational study
(Table 2). Some of these 30 items differ between trials
and observational studies, mainly from a methodological
point of view. We enclosed our SAP and study protocol
in the supplements for illustrative purposes, so that it
may serve as an example document for developing SAPs
for other observational studies.
Main reasons for ignoring two items (6%) were that
these recommendations were specifically limited to tri-
als, that is descriptions on randomisation and definition
of adherence to the intervention.
Discussion
Preregistration of protocols and SAPs for observational
studies has been intensely debated [12–15, 38–48]. Op-
posing authors state that preregistration creates the false
assumption that data are of high quality, would discour-
age publication of important accidental findings, and
would delay these publications due to bureaucratic pro-
cedures [38–44]. Authors in favour argue that preregis-
tration of protocols and SAPs distinguishes prespecified
hypotheses from data dredging expeditions, ensures that
methods can be replicated and findings confirmed, and
reduces selective outcome reporting and publication bias
[45–49]. Our present recommendations show the large
similarities between SAPs for randomised clinical trials
and observational studies and are parallel to our previ-
ous recommendations to publicly and transparently
communicate all aspects of randomised clinical trials as
well as observational studies from protocol to final re-
sults [1].
Observational studies are prone to confounding by
indication, residual confounding, and flaws in data col-
lection [50]. We argue that publication of a SAP in-
creases the chance that hypotheses are adequately
powered and investigated in the appropriate study
population in which also all known confounders, medi-
ators, and covariates are measured [46, 51]. Since
credibility and replicability of findings in observational
studies are a concern to many [11–15, 46, 52], the pub-
lication of a SAP allows better validation of findings in
independent cohorts in an identical methodological and
statistical manner. Furthermore, the concern that im-
portant findings will remain unpublished is less
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Table 2 Recommended content of statistical analysis plans for observational studies
Section/Item Index Description for observational studies
Section 1: Administrative information
Title and study registration 1a Descriptive title that matches the protocol, with SAP either as a forerunner or subtitle, and study
acronym
1b Study registration number
SAP version 2 SAP version number with dates
Protocol version 3 Reference to version of protocol being used
SAP revisions 4a SAP revision history
4b Justification for each SAP revision
4c Timing of SAP revisions in relation to planned repetitive analyses
Roles and responsibility 5 Names, affiliations, and roles of SAP contributors
Signatures of: 6a Person writing the SAP
6b Senior statistician responsible
6c Chief investigator/clinical lead
Section 2: Introduction
Background and rationale 7 Synopsis of study background and rationale including a brief description of research question and brief
justification for undertaking the study
Objectives 8 Description of specific objectives and hypotheses, including secondary objectives
Section 3: Study methods
Study design 9 Brief description of study design including type of study (e.g. case-control, cross-sectional or cohort
study)
Power considerations 10 In case of an unspecified sample size, provide power calculations for (at least) the primary analysis or
present a detectable difference with a specified power*
Framework 11 Superiority, equivalence, or noninferiority hypothesis testing framework, including which comparisons
will be presented on this basis
Statistical interim analyses and
stopping guidance
12a Information on repetitive analyses specifying what repetitive analyses will be carried out and listing of
time points
12b Any planned adjustment of the significance level due to repetitive analyses
12c Details of guidelines for stopping the study early
Timing of final analysis 13 Timing of final analysis, e.g., all outcomes analysed collectively or timing stratified by planned length of
follow-up*
Timing of outcome assessments 14 Time points at which the outcomes are measured including visit “windows”
Section 4: Statistical principles
Confidence intervals and P-values 15 Level of statistical significance*
16 Description and rationale for any adjustment for multiplicity and, if so, detailing how the type 1 error is
to be controlled*
17 Confidence interval to be reported
Adherence and protocol
deviations
18a Definition of protocol deviations for the trial
18b Description of which protocol deviations will be summarized
Analysis populations 19 Definition of analysis populations, e.g., intention to treat, per protocol, complete case, safety
Section 5: Study Population
Screening data 20 Reporting of screening data (if collected) to describe representativeness of study sample
Eligibility 21 Summary of eligibility criteria
Recruitment 22 Information to be included in the STROBE flow diagram*
Withdrawal/follow-up 23a Level of withdrawal, e.g., dropouts after inclusion or refusal to be contacted for additional information
23b Timing of withdrawal/lost to follow-up data
23c Reasons and details of how withdrawal/lost to follow-up data will be presented
Baseline patient characteristics 24a List of baseline characteristics to be summarized
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worrying than a lot of accidental findings getting pub-
lished, creating confusion by researchers hunting hy-
pothesis without real content. For the credibility of an
‘eye-catching’ finding to prevail, it still has to be repli-
cated in a methodological sound study with an a priori
hypothesis and an adequate statistical power. Irrespect-
ive of its potential benefits, publishing a SAP would at
least do no harm and may be seen as an independent
transparent determinant of validity.
Conclusions
Both a protocol and a SAP in the public domain are
equally helpful for both observational studies and ran-
domised clinical trials [45]. By applying the guideline
for the content of SAPs for clinical trials to our obser-
vational study we can conclude that more than 90% of
the recommended content based on an extensive Del-
phi survey suits an observational study as well. There
are only few adjustments needed for guidance of a
SAP for observational studies when compared to a
SAP for randomised clinical trials. In absence of SAP
guidelines, we think that current recommend contents
of SAPs for clinical trials could serve as a structure for
SAPs of observational studies.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12874-019-0879-5.
Additional file 1: statistical analysis plan of the Simple Intensive Care
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